Anilides
Cayman Chemical LeflunomIde 50mg
A prodrug form of A-771726; inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle; inhibits proliferation and activation of T cells at 25 and 100 µM, respectively, for naïve and memory CD4+ T cells; reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis at 35 mg/kg per day
Cayman Chemical LeflunomIde 100mg
A prodrug form of A-771726; inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle; inhibits proliferation and activation of T cells at 25 and 100 µM, respectively, for naïve and memory CD4+ T cells; reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis at 35 mg/kg per day
Cayman Chemical LeflunomIde 25mg
A prodrug form of A-771726; inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle; inhibits proliferation and activation of T cells at 25 and 100 µM, respectively, for naïve and memory CD4+ T cells; reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis at 35 mg/kg per day
Cayman Chemical LeflunomIde 500mg
A prodrug form of A-771726; inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle; inhibits proliferation and activation of T cells at 25 and 100 µM, respectively, for naïve and memory CD4+ T cells; reduces and prevents inflammation in a proteoglycan-induced mouse model of rheumatoid arthritis at 35 mg/kg per day
Medchemexpress LLC Leflunomide | 75706-12-6 | C12H9F3N2O2 | 500 MG
Leflunomide is a pyrimidine synthesis inhibitor, primarily functioning by inhibiting dihydroorotate dehydrogenase (DHODH), and is recognized as a disease-modifying antirheumatic agent. This prodrug inhibits the proliferation of mononuclear and T-cells and acts as an inhibitor of several protein tyrosine kinases, with IC50 values ranging from 30 mM to 100 mM in in vitro assays. It also interferes with cell cycle progression and utilizes p53-dependent mechanisms to prevent the expansion of activated and autoimmune lymphocytes.
- Inhibits dihydroorotate dehydrogenase (DHODH)
- Acts as a disease-modifying antirheumatic agent
- Inhibits proliferation of mononuclear and T-cells
- Functions as an inhibitor of several protein tyrosine kinases
- Inhibits p59fyn and p56lck activity in tyrosine kinase assays
- Inhibits calcium mobilization in Jurkat cells
- Prevents expansion of activated and autoimmune lymphocytes
Apexbio Technology LLC Leflunomide 75706-12-6 10mM (in 1mL DMSO)
Leflunomide (CAS 75706-12-6) is a small-molecule agonist targeting the aryl hydrocarbon receptor (AHR) pathway It is designed to modulate AHR signaling thereby enhancing regulatory T cell (Treg) numbers altering inflammatory cytokine profiles and influencing immune responses Leflunomide exerts its biological activity primarily through metabolic conversion to its active metabolite Teriflunomide (A771726) which mediates immunosuppressive effects It enhances IL-10 production and suppresses IL-17 and IL-23 secretion In cell-based studies leflunomide demonstrates anti-proliferative efficacy in human medullary thyroid carcinoma cells (MTC-TT) with IC50 values ranging from approximately 30 to 50 M depending on specific assay conditions Based on these pharmacological properties leflunomide holds research potential in ischemia-reperfusion renal injury sepsis-induced intestinal oxidative stress and tumor proliferation inhibition models
Medchemexpress LLC Leflunomide | 75706-12-6 | 99.8% | C12H9F3N2O2 | 1 ML
Leflunomide is a pyrimidine synthesis inhibitor that acts by inhibiting dihydroorotate dehydrogenase (DHODH), functioning as a disease-modifying antirheumatic agent. It is an immunomodulatory drug that prevents the expansion of activated and autoimmune lymphocytes by interfering with cell cycle progression due to inadequate rUMP production and by utilizing mechanisms involving p53. This product is for research use only.
- Inhibits dihydroorotate dehydrogenase (DHODH)
- Functions as a disease-modifying antirheumatic agent
- Inhibits proliferation of mononuclear and T-cells
- Inhibits several protein tyrosine kinases
- Prevents expansion of activated and autoimmune lymphocytes
Medchemexpress LLC NAP-2/CXCL7 Human 10ug
CXCL7 (also known as neutrophil activating peptide 2 NAP-2) is a platelet-derived growth factor that belongs to the ELR CXC chemokine family functioning as a potent chemoattractant and activator of neutrophils through binding to its receptor CXCR2[1] NAP-2/CXCL7 Protein Human (CHO) is produced in CHO cells and consists of 70 amino acids (A59-D128)
Medchemexpress LLC NAP-2/CXCL7 Rat CH 2ug
CXCL7 (also known as neutrophil activating peptide 2 NAP-2) is a platelet-derived growth factor that belongs to the ELR CXC chemokine family functioning as a potent chemoattractant and activator of neutrophils through binding to its receptor CXCR2[1] NAP-2/CXCL7 Protein Rat (CHO) is produced in CHO cells and consists of 62 amino acids (I46-I107)
Apexbio Technology LLC S-Nitroso-N-acetyl-DL-penicillamine 67776-06-1 10mg
S-Nitroso-N-acetyl-DL-penicillamine (SNAP CAS 67776-06-1) is a low-molecular-weight nitric oxide (NO) donor that facilitates the sustained release of NO in biological systems By elevating NO levels SNAP stimulates soluble guanylate cyclase activity resulting in increased cyclic guanosine monophosphate (cGMP) production and subsequent modulation of downstream signaling pathways These actions contribute to vascular smooth muscle relaxation and vasodilation SNAP is widely employed in experimental studies to investigate NO-mediated mechanisms including inhibition of platelet aggregation and regulation of inflammatory responses and serves as a valuable reagent for probing NO signaling in cultured cells
Apexbio Technology LLC S-Nitroso-N-acetyl-DL-penicillamine 67776-06-1 50mg
S-Nitroso-N-acetyl-DL-penicillamine (SNAP CAS 67776-06-1) is a low-molecular-weight nitric oxide (NO) donor that facilitates the sustained release of NO in biological systems By elevating NO levels SNAP stimulates soluble guanylate cyclase activity resulting in increased cyclic guanosine monophosphate (cGMP) production and subsequent modulation of downstream signaling pathways These actions contribute to vascular smooth muscle relaxation and vasodilation SNAP is widely employed in experimental studies to investigate NO-mediated mechanisms including inhibition of platelet aggregation and regulation of inflammatory responses and serves as a valuable reagent for probing NO signaling in cultured cells
Apexbio Technology LLC S-Nitroso-N-acetyl-DL-penicillamine 67776-06-1 25mg
S-Nitroso-N-acetyl-DL-penicillamine (SNAP CAS 67776-06-1) is a low-molecular-weight nitric oxide (NO) donor that facilitates the sustained release of NO in biological systems By elevating NO levels SNAP stimulates soluble guanylate cyclase activity resulting in increased cyclic guanosine monophosphate (cGMP) production and subsequent modulation of downstream signaling pathways These actions contribute to vascular smooth muscle relaxation and vasodilation SNAP is widely employed in experimental studies to investigate NO-mediated mechanisms including inhibition of platelet aggregation and regulation of inflammatory responses and serves as a valuable reagent for probing NO signaling in cultured cells